​

presentations​

presentations page 2013

10 Dec 2013

Appendix 3Z - Final Directors Interest Notice

read more >>
06 Dec 2013

Appendix 3X - Initial Director's Interest Notice

read more >>
03 Dec 2013

Circadian CEO and Board Changes

read more >>
29 Nov 2013

Results of Annual General Meeting

read more >>
29 Nov 2013

CEOs Address To Annual General Meeting

read more >>
29 Nov 2013

Chairmans Address To Annual General Meeting

read more >>
29 Nov 2013

Appendix 3Z - Final Directors Interest Notice

read more >>
29 Nov 2013

Director Resignation

read more >>
27 Nov 2013

Phase 1b oncology trial completed

read more >>
15 Nov 2013

Federal Government R&D Tax Incentive - Circadian To Receive Over $2.5m

read more >>
04 Nov 2013

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer

read more >>
30 Oct 2013

Opthea Signs Manufacturing Agreement for Lead Product

read more >>
28 Oct 2013

Annual Report / Notice of AGM and Proxy

read more >>
17 Oct 2013

Phase 1a clinical oncology trial with VGX-100 update

read more >>
01 Oct 2013

Revised AGM details

read more >>
11 Sep 2013

Analyst Investment Report on Circadian Website

read more >>
10 Sep 2013

New Company Secretary

read more >>
28 Aug 2013

Open Briefing

read more >>
28 Aug 2013

2012/13 Preliminary Annual Results

read more >>
15 Jul 2013

Circadian moves to new South Yarra office

read more >>
15 Jul 2013

The FDA has taken the first step in approving VEGF-D diagnostics as a test to monitor LAM

read more >>
02 Jul 2013

FDA grants humanitarian use device designation to VEGF-D kit

read more >>
17 Jun 2013

US Patent Granted Covering use of VEGFR-3

read more >>
04 Jun 2013

VGX-100 Phase 1 Oncology Trial Presented at ASCO 2013

read more >>
04 Jun 2013

VGX-100 Poster Presentation at ASCO

read more >>
27 May 2013

Change of Director's Interest Notice

read more >>
24 May 2013

Open Briefing: VGX-300 Potential in AMD

read more >>
23 May 2013

Change of Director's Interest Notice

read more >>
20 May 2013

Change of Director's Interest Notice

read more >>
17 May 2013

Progress of VGX-100 Phase 1 trial to be presented at ASCO

read more >>
09 May 2013

VEGF-C shown to have major role in Age-Related Macular Degeneration (AMD)

read more >>
08 Mar 2013

Circadian grants world-wide licence to Santa Cruz Biotechnology Inc

read more >>
06 Mar 2013

Edison Research publishes updated analysis on Circadian. Values the company at $1.93/share

read more >>
27 Feb 2013

Circadian commences worldwide marketing & sales of unique VEGF-C & VEGF-D products as research reagents

read more >>
25 Feb 2013

Open Briefing: Interview with CEO & MD Robert Klupacs on H1 Results & Outlook

read more >>
22 Feb 2013

Appointment of CFO and Company Secretary

read more >>
20 Feb 2013

Resignation of CFO and Company Secretary

read more >>
18 Feb 2013

Half Year Report & Accounts

read more >>
07 Feb 2013

R&D Tax Incentive - Circadian Receives $1.3m

read more >>
04 Feb 2013

VGX-100 Phase 1 Clinical Trial Program Update

read more >>
10 Jan 2013

Company Presentation at JP Morgan Biotech Showcase

read more >>